Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trichomonas vaginalis | m-phase inducer phosphatase, putative | 0.00670932 | 0.204501 | 0.5 |
Onchocerca volvulus | 0.00670932 | 0.204501 | 0.5 | |
Brugia malayi | Rhodanese-like domain containing protein | 0.00670932 | 0.204501 | 1 |
Onchocerca volvulus | 0.00670932 | 0.204501 | 0.5 | |
Onchocerca volvulus | 0.00670932 | 0.204501 | 0.5 | |
Entamoeba histolytica | rodhanase-like domain containing protein | 0.00670932 | 0.204501 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.00670932 | 0.204501 | 1 |
Echinococcus granulosus | glutamate receptor NMDA | 0.0127763 | 0.653097 | 0.858208 |
Echinococcus multilocularis | glutamate receptor, ionotrophic, AMPA 3 | 0.00469167 | 0.0553161 | 0.0726886 |
Echinococcus multilocularis | Glutamate receptor, ionotropic kainate 2 | 0.00469167 | 0.0553161 | 0.0726886 |
Trichomonas vaginalis | mitotic inducer phosphatase CDC25, putative | 0.00670932 | 0.204501 | 0.5 |
Trichomonas vaginalis | cdc25b, putative | 0.00670932 | 0.204501 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.00614867 | 0.163047 | 0.797288 |
Echinococcus multilocularis | m phase inducer phosphatase(cdc25) | 0.00670932 | 0.204501 | 0.268727 |
Echinococcus granulosus | Glutamate receptor ionotropic kainate 2 | 0.00469167 | 0.0553161 | 0.0726886 |
Echinococcus multilocularis | Glutamate receptor, ionotropic kainate 2 | 0.00469167 | 0.0553161 | 0.0726886 |
Echinococcus granulosus | Glutamate receptor ionotropic kainate 2 | 0.00469167 | 0.0553161 | 0.0726886 |
Entamoeba histolytica | rodhanase-like domain containing protein | 0.00670932 | 0.204501 | 0.5 |
Echinococcus granulosus | nmda type glutamate receptor | 0.0142357 | 0.761001 | 1 |
Brugia malayi | Rhodanese-like domain containing protein | 0.00670932 | 0.204501 | 1 |
Echinococcus granulosus | m phase inducer phosphatasecdc25 | 0.00670932 | 0.204501 | 0.268727 |
Echinococcus multilocularis | glutamate receptor NMDA | 0.0127763 | 0.653097 | 0.858208 |
Trichomonas vaginalis | mitotic inducer phosphatase CDC25, putative | 0.00670932 | 0.204501 | 0.5 |
Schistosoma mansoni | glutamate receptor NMDA | 0.017468 | 1 | 1 |
Echinococcus granulosus | glutamate receptor 2 | 0.00469167 | 0.0553161 | 0.0726886 |
Trichomonas vaginalis | cdc25c, putative | 0.00670932 | 0.204501 | 0.5 |
Echinococcus granulosus | Glutamate receptor ionotropic kainate 2 | 0.00469167 | 0.0553161 | 0.0726886 |
Schistosoma mansoni | m-phase inducer phosphatase(cdc25) | 0.00670932 | 0.204501 | 0.204501 |
Onchocerca volvulus | 0.00670932 | 0.204501 | 0.5 | |
Loa Loa (eye worm) | hypothetical protein | 0.00614867 | 0.163047 | 0.797288 |
Trichomonas vaginalis | mitotic inducer phosphatase CDC25, putative | 0.00670932 | 0.204501 | 0.5 |
Trichomonas vaginalis | m-phase inducer phosphatase, putative | 0.00670932 | 0.204501 | 0.5 |
Echinococcus multilocularis | glutamate receptor 2 | 0.00469167 | 0.0553161 | 0.0726886 |
Loa Loa (eye worm) | hypothetical protein | 0.00670932 | 0.204501 | 1 |
Echinococcus multilocularis | Glutamate receptor, ionotropic kainate 2 | 0.00469167 | 0.0553161 | 0.0726886 |
Echinococcus granulosus | glutamate receptor ionotrophic AMPA 3 | 0.00469167 | 0.0553161 | 0.0726886 |
Entamoeba histolytica | rodhanase-like domain containing protein | 0.00670932 | 0.204501 | 0.5 |
Echinococcus granulosus | nmda type glutamate receptor | 0.0135245 | 0.708413 | 0.930897 |
Trichomonas vaginalis | cdc25b, putative | 0.00670932 | 0.204501 | 0.5 |
Echinococcus multilocularis | nmda type glutamate receptor | 0.0142357 | 0.761001 | 1 |
Echinococcus multilocularis | nmda type glutamate receptor | 0.0135245 | 0.708413 | 0.930897 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Activity (functional) | NOVARTIS: Antimalarial liver stage activity measured as a greater than 50% reduction in Plasmodium yoelii schizont area in HepG2-A16-CD81 cells at 10uM compound concentration, determined by immuno-fluorescence. | ChEMBL. | 22096101 | |
CC50 (functional) | > 96.06 uM | Huh7 cytotoxicity for Pf inhibitors | Novartis-GNF Malaria Box. | No reference |
CC50 | > 96.06 uM | NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7) | ChEMBL. | 18579783 |
EC50 (functional) | = 0.466 uM | W2 Pf proliferation inhibition | Novartis-GNF Malaria Box. | No reference |
EC50 (functional) | = 0.466 uM | NOVARTIS: Inhibition of Plasmodium falciparum W2 (drug-resistant) proliferation in erythrocyte-based infection assay | ChEMBL. | 18579783 |
EC50 (functional) | = 1.32 uM | PF proliferation inhibition 3D7 | Novartis-GNF Malaria Box. | No reference |
EC50 (functional) | = 1.32 uM | NOVARTIS: Inhibition of Plasmodium falciparum 3D7 (drug-susceptible) proliferation in erythrocyte-based infection assay | ChEMBL. | 18579783 |
IFI promiscuity index | = 0 | IFI promiscuity index | Novartis-GNF Malaria Box. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 | 18579783 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.